🇺🇸 FDA
Pipeline program

Nicotine polacrilex

2014P002495-01

Phase 1 small_molecule completed

Quick answer

Nicotine polacrilex for Depressive Disorder is a Phase 1 program (small_molecule) at BRIGHT MINDS BIOSCIENCES INC. with 1 ClinicalTrials.gov record(s).

Program details

Company
BRIGHT MINDS BIOSCIENCES INC.
Indication
Depressive Disorder
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials